Cenegermin in Pediatric Neurotrophic Keratopathy

Cornea. 2019 Nov;38(11):1450-1452. doi: 10.1097/ICO.0000000000002112.

Abstract

Purpose: We report a case of neurotrophic keratopathy (NK) arising after surgery for rhabdomyosarcoma of the jaw successfully treated with Cenegermin eye drops (Oxervate; Dompé Farmaceutici, Milan, Italy) in a 3-year-old boy.

Methods: At the age of 1 year, the boy underwent surgery for rhabdomyosarcoma of the jaw, followed by radiotherapy. Subsequent NK was initially treated with preservative-free artificial tears, topical combination of dexamethasone 0.1% and netilmicin 0.3% (Netildex; Sifi, Catania, Italy), and moxifloxacin 0.5% (Vigamox; Alcon, Fort Worth, TX), followed by 10 cycles of a topical eye biopolymer containing a poly-carboxymethyl glucose sulfate solution (Cacicol; Theà, Clermont-Ferrand, France) and 4 amniotic membrane transplantations. Keratopathy was recalcitrant to therapy and tissue transplant. Therapy was switched to Cenegermin eye drops 6 times daily for 8 weeks.

Results: Complete healing of the corneal epithelium was achieved at 3 weeks into treatment.

Conclusions: Cenegermin was effective in restoring corneal integrity in this pediatric patient with NK.

Publication types

  • Case Reports

MeSH terms

  • Child, Preschool
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Drug Administration Schedule
  • Epithelium, Corneal / drug effects
  • Epithelium, Corneal / pathology*
  • Humans
  • Male
  • Nerve Growth Factor / administration & dosage*
  • Ophthalmic Solutions / administration & dosage
  • Recombinant Proteins
  • Slit Lamp Microscopy
  • Treatment Outcome

Substances

  • Ophthalmic Solutions
  • Recombinant Proteins
  • Nerve Growth Factor
  • cenegermin